Several studies have demonstrated that high serum IGF1 and low serum IGFBP3 are associated with an increased risk of prostate, breast, colorectal and lung cancer, and HCC[99-101], probably due to the high bioavailability of mitogenic IGF1. The gene discussed is IGF1; the disease is hepatocellular carcinoma.